Introduction: Despite advances in systemic therapy, metastatic and recurrent pancreatic cancer remains associated with poor survival. Following progression on first-line gemcitabine-based chemotherapy, treatment options have historically been limited.
Introduction:
Despite advances in systemic therapy, metastatic and recurrent pancreatic cancer remains associated with poor survival. Following progression on first-line gemcitabine-based chemotherapy, treatment options have historically been limited. The introduction of nanoliposomal irinotecan (nal-IRI) combined with 5-fluorouracil and leucovorin (5-FU/LV) represented an important therapeutic advance, demonstrating improved efficacy in clinical trials. However, whether this benefit translates into routine clinical practice has remained uncertain.
Problem Statement:
Clinical trial populations often differ from real-world patients encountered in daily oncology practice. Consequently, it is important to determine whether the availability of nal-IRI has meaningfully improved survival outcomes for patients with metastatic or recurrent pancreatic cancer outside controlled trial settings.
Summary:
This real-world study compared treatment outcomes in patients with metastatic or recurrent pancreatic cancer before and after the introduction of nal-IRI plus 5-FU/LV as a second-line treatment option. The investigators found that while overall survival from the start of first-line therapy remained largely unchanged, patients treated in the era following nal-IRI availability experienced significantly improved outcomes after progression on first-line treatment. Both progression-free survival and overall survival from initiation of second-line therapy were prolonged following the introduction of nal-IRI-based treatment. Furthermore, multivariable analysis identified treatment in the nal-IRI era as an independent predictor of improved second-line survival. These findings suggest that access to effective second-line therapy can meaningfully influence outcomes even in a disease with historically limited treatment options. Importantly, the survival benefits were achieved with an acceptable safety profile, supporting the feasibility of this regimen in routine practice. The study provides valuable real-world evidence confirming that the benefits observed in clinical trials can be translated into everyday clinical care. Overall, the results support nal-IRI plus 5-FU/LV as an important component of the treatment sequence for metastatic and recurrent pancreatic cancer and highlight the growing importance of effective second-line therapy in improving patient outcomes.
Introduction: Circulating tumor DNA (ctDNA) has emerged as a promising noninvasive biomarker for monitoring treatment response and residual disease in solid tumors. However, its prognostic value during neoadjuvant chemotherapy (NAC) for localized pancreatic ductal adenocarcinoma...
Introduction: Aspirin is one of the few interventions proven to reduce colorectal and other Lynch syndrome–associated cancers. The earlier CaPP2 trial established 600 mg daily aspirin as an effective chemopreventive strategy, but concerns regarding long-term...
Introduction: The TOPAZ-1 trial established durvalumab combined with gemcitabine and cisplatin (GemCis) as the first immunotherapy-based first-line standard of care for advanced biliary tract cancer (BTC). However, long-term survival outcomes and durability of benefit beyond...
Introduction: Somatostatin receptor (SSTR) PET/CT has become indispensable for diagnosing, staging, and monitoring neuroendocrine tumors (NETs). However, until now, there has been no standardized method for assessing treatment response using SSTR PET imaging. This international...
Introduction: Staging laparoscopy (SL) is recommended for patients with locally advanced gastric cancer to detect occult peritoneal metastases before curative treatment. However, its real-world utilization across Europe remains uncertain. This large GASTRODATA study evaluated the...
Introduction: Neoadjuvant immune checkpoint inhibitors have transformed the management of mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) locally advanced colorectal cancer, achieving unprecedented pathological response rates. Experimental evidence suggests that cyclooxygenase-2 (COX-2) inhibition may enhance...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.